Cite
Cristaudo A, Graceffa D, Pimpinelli F, et al. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J Eur Acad Dermatol Venereol. 2021;doi: 10.1111/jdv.17861.
Cristaudo, A., Graceffa, D., Pimpinelli, F., Sperati, F., Spoletini, G., Bonifati, C., Pellini, R., Lora, V., Pontone, M., Di Bella, O., Bracco, D., & Morrone, A. (2021). Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17861
Cristaudo, A, et al. "Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2021). doi: https://doi.org/10.1111/jdv.17861
Cristaudo A, Graceffa D, Pimpinelli F, Sperati F, Spoletini G, Bonifati C, Pellini R, Lora V, Pontone M, Di Bella O, Bracco D, Morrone A. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J Eur Acad Dermatol Venereol. 2021 Dec 11; doi: 10.1111/jdv.17861. Epub 2021 Dec 11. PMID: 34897821.
Copy
Download .nbib